Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 23 clinical trials
A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer

This phase I trial investigates the side effects and best dose of using a modified measles virus, MV-s-NAP, in treating patients with invasive breast cancer that has spread to other places in the body (metastatic). Both the unmodified vaccination measles virus (MV-Edm) and this modified virus (MV-s-NAP) have been shown …

progesterone
growth factor
measurable disease
cancer
progesterone receptor
  • 0 views
  • 25 Jan, 2021
Trial of H3B-6545 in Women With Locally Advanced or Metastatic Estrogen Receptor-positive HER2 Negative Breast Cancer

The purpose of phase 1 is to determine safety, tolerability and pharmacokinetics (PK) of H3B-6545 in women with locally advanced or metastatic estrogen receptor (ER)-positive, human epidermal growth factor 2 (HER2)-negative breast cancer. The purpose of phase 2 is to estimate the efficacy of H3B-6545 in terms of best overall …

human epidermal growth factor
breast cancer
measurable disease
HER2
cancer
  • 114 views
  • 25 Jan, 2021
  • 20 locations
Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer

This phase I/II trial studies the best dose of pembrolizumab and binimetinib and how well it works when giving together with pembrolizumab in treating patients with triple negative breast cancer that has spread to other parts of the body. Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different …

progesterone
cancer
triple negative breast cancer
measurable disease
ejection fraction
  • 16 views
  • 26 Jan, 2021
  • 2 locations
TPIV100 and Sargramostim for the Treatment of HER2 Positive Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

This phase II trial studies how well TPIV100 and sargramostim work in treating patients with HER2 positive, stage II-III breast cancer that has remained after chemotherapy and surgery. It also studies why some HER2 positive breast cancer patients respond better to chemotherapy in combination with trastuzumab and pertuzumab. TPIV100 is …

progesterone
HER2
cancer
residual tumor
vaccine therapy
  • 0 views
  • 24 Jan, 2021
  • 3 locations
Testing the Addition of an Anti-cancer Drug Berzosertib to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive HER2 Negative Breast Cancer

This phase Ib trial studies the best dose of berzosertib when given together with the usual treatment (radiation therapy) in treating patients with triple negative or estrogen receptor and/or progesterone receptor positive, HER-2 negative breast cancer. Berzosertib may stop the growth of tumor cells by blocking some of the enzymes …

carcinoma in situ
progesterone
cancer
triple negative breast cancer
HER2
  • 0 views
  • 04 Feb, 2021
  • 5 locations
Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca

This study is a 2-cohort, open-label, multicenter, phase 2 study of a short course of immunotherapy consisting of sequential decitabine followed by pembrolizumab administered prior to a standard neoadjuvant chemotherapy regimen for patients with locally advanced HER2-negative breast cancer. The primary efficacy objective is to determine if the immunotherapy increases …

progesterone
cyclophosphamide
cancer
HER2
doxorubicin
  • 64 views
  • 24 Jan, 2021
  • 5 locations
Incidence and Severity of Diarrhea in Patients With Stage II-IIIC HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib

This phase II trial studies the incidence and severity of diarrhea in patients with stage II-IIIC HER2 Positive breast cancer treated with trastuzumab and neratinib. Trastuzumab is a form of targeted therapy because it attaches itself to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors. …

breast cancer
HER2
cancer
breast cancer staging
ejection fraction
  • 62 views
  • 24 Feb, 2021
  • 2 locations
Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer

This phase II trial studies the side effects and how well radiation therapy works in treating patients with stage 0-II breast cancer. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.

carcinoma in situ
cancer
partial breast irradiation
carcinoma in situ of the cervix
lumpectomy
  • 14 views
  • 25 Jan, 2021
  • 2 locations
Image-guided Targeted Doxorubicin Delivery With Hyperthermia to Optimize Loco-regional Control in Breast Cancer

In this phase I feasibility study, the investigators evaluate the combination of lyso-thermosensitive liposomal doxorubicin (LTLD, ThermoDox) with local hyperthermia and cyclophosphamide (C), for the local treatment of the primary breast tumour in patients with metastatic breast cancer. When heated to 40-43 degrees Celsius (C), LTLD releases a very high …

cyclophosphamide
breast cancer
serum pregnancy test
breast adenocarcinoma
cancer
  • 3 views
  • 25 Feb, 2021
  • 1 location
A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin

This is a randomized controlled trial of HER-2 positive breast cancer patients treated with lapatinib and paclitaxel vs herceptin and paclitaxel with sequential and synchronous anthracycline

breast cancer
cancer
paclitaxel
primary tumor
her-2
  • 42 views
  • 21 Jan, 2021
  • 1 location